Life Biosciences Submits IPO Prospectus Following First-in-Human ER-100 Rejuvenation Gene Therapy Injection

David Sinclair, a genetics professor at Harvard University (David Sinclair), Research on Aging30Year.2026Year3In the month, he shared externally that the first clinical trial of human reverse aging gene therapy had begun, and the first participant had started receiving injections.

1At the end of the month, Sinclair co-founded the biotechnology company Life BiosciencesOfficially received the United States Food and Drug Administration (FDA) approved, launching this clinical trial in humans. Drug codeER-100。3At the beginning of the month, the clinical trial center officially transitioned from "planned" to "recruiting."”。

Entering human clinical trials is a milestone in the field of anti-aging research. This marks the first time in human history that "cellular reprogramming" (Cellular Reprogramming) technology applied to the human body.

David Sinclair in2Accepted multiple interviews before and after the month, providing an in-depth breakdown of this research.

The human trial launched this time targets two typesDiseases Leading to Blindness。ER-100The specific steps of the experiment are to use adeno-associated virus (AAV) as a vector, the three genesOct4、Sox2、Klf4(Collectively referred to asOSK), directly injected into the patient's eyeball, allowing these genes to enter the damaged retinal ganglion cells.

The trial also designed a“Switch”The mechanism is that the introduced gene will only be activated when the patient takes a low dose of the antibiotic doxycycline; once the medication is stopped, gene expression will be turned off. This is considered the essence of the trial design.

OSKThree genes come from Japanese scientist Shinya Yamanaka（Shinya Yamanaka）The research found that. Shinya Yamanaka used four genes to reverse adult cells into stem cells back in the day.

2012 The discovery by Shinya Yamanaka, winner of the Nobel Prize in Physiology or Medicine: By introducing four specific transcription factors into adult cells, later referred to as“Yamanaka Factors”, which can be reprogrammed into a pluripotent state similar to embryonic stem cells.

These four factors are respectively Oct4、Sox2、Klf4Andc-Myc. However, becausec-MycClosely related to tumor formation; in early experiments, mice simultaneously introduced with four factors experienced massive deaths and tumor growth.

The Sinclair team took a different approach: they did not want to revert cells back to the stem cell state, as that would be too risky. They only wanted to make the cells "slightly younger," while still remaining themselves.

Thus, the Sinclair team eliminated the highest cancer riskc-Myc, only the first three factors are selected.Add a "switch" mechanism. This kind of "partial reprogramming”A strategy aimed at restoring cells to a youthful state while preventing them from "forgetting" their identity and turning into primitive stem cells with cancerous potential.

Sinclair said in a simulationNAION In the monkey experiment, injectionER-100Significantly restored the electrical signal response of retinal ganglion cells (pERG), which proves that reprogramming is effective and safe in eyes that are highly similar in structure to human eyes.

2020 In a study published in the journal Nature, Sinclair's team demonstrated that this technology could reverse vision loss in mice with glaucoma and even regenerate damaged optic nerves.

For the choice to target eye diseases first,Life Biosciences Chief Executive OfficerJerry McLaughlin Explained in an interview with Fortune magazine that the company has adopted a“Phased Strategy”。

The reason also lies in the United StatesFDANot applicable“Aging”Itself is considered a disease. This means any“Anti-aging”Therapies aimed at these goals cannot be approved through the conventional clinical trial pathway.

MIT Technology Review pointed out in an article that,Life Biosciences And other similar companies must target their therapies at treating specific age-related diseases, such as vision loss, liver fibrosis, or neurodegenerative disorders, rather than directly addressing the aging process itself.

Life BiosciencesTwo eye diseases were selected, which in2026Year1Month28The statement released on the 1st shows that the United StatesFDAApproval for its new drug's Phase I clinical trial in humans for primary open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION）。

NAION Called“Eye Stroke”, is50The most common acute optic neuropathy in people over a certain age, currently with no approved treatment options. Glaucoma is the second leading cause of blindness globally, and according to data from the U.S. Centers for Disease Control and Prevention, the disease in China...64To84Particularly prevalent among adults.

The trial will first be conducted in approximately12Evaluate the safety in patients while observing whether the therapy can restore vision to some extent.

According to the trial plan, patients will take doxycycline.8Weeks, while using steroids to suppress potential inflammatory responses. First, at most6Test two different doses on patients with glaucoma, then select one dose for the maximum number.6NameNAIONPatient.

Sinclair's comments on this human trial in the podcast were,Even partial restoration of vision would represent more than just an ophthalmological breakthrough—it would demonstrate that the information of aging can be retrieved within a living body. The eyes are just the beginning. Next come the liver, the brain, the skin, and eventually the entire body.

Sinclair has adopted a pragmatic and incremental strategy, but this also means“Full-body Rejuvenation”If truly feasible, there is still a long way to go before clinical application.

"By the time we figure out the cause of aging, we'll find it's extremely obvious, and not complicated."2026Year1Month, Elon·Musk said at the Davos Forum that aging is a“Problems that can be solved”。

Sinclair on social platformsXResponse to Musk:“Aging has a relatively simple explanation and is apparently reversible. Clinical trials will begin soon.”Musk immediately followed up with a question:“ER-100？”Sinclair gave an affirmative answer.

Sinclair has long advocated“Theory of Aging Information”（Information Theory of Aging). He believes that,ER-100Not just a drug, it is the first human validation of the Information Theory of Aging. The core logic is: cells do not lose the genetic information they had in their youth; rather, it is the epigenetic information—chemical markers that determine which genes are turned on or off at specific times—that gradually becomes lost and disordered.

He once made an analogy: IfDNAIt is the digital information on a CD, then aging is like scratches on the surface of the CD, the information itself is still there, but it becomes difficult to read. AndER-100It is like“Polishing Agent”, restoring the cell's ability to read youthful instructions.

“Reprogramming is like in the biological worldAI, is a hot spot that everyone is investing in.”Karl, a famous angel investor in Silicon Valley·Pufleag (Karl Pfleger) In an interview about "Longevity Biotechnology," he compared reprogramming technology toAI, is because it has extremely strong versatility and platform attributes.——By resetting the cell clock through specific factors (such as Yamanaka factors), it can be likeAIProcess big data in the same way, and alter the aging process of organisms on a large scale.

However, Carl·Pfluger also pointed out that it is currently just a proof of concept, and there is still a distance from practical application.Very Long Distance:“The optimistic scenario is that it might solve certain blindness issues for some people and drive research on other indications. But this doesn’t mean your doctor will soon be able to prescribe a pill to make you young again.”。

Risks and controversies surrounding this technology have always existed. Although it showed astonishing results in experiments on mice and non-human primates, such as successfully restoring the vision of blind mice,ER-100Clinical trials in humans still face significant challenges.

British Startup Shift Bioscience CEODaniel IvesIn an interview with MIT Technology Review,Life BiosciencesThe Three-Factor Combination Used“Not the optimal rejuvenation version”, because these factors may activate hundreds of downstream genes, in some cases potentially causing cells to fully revert to a primitive stem cell state.

Moreover, the long-term safety remains questionable, such as whether the long-term activation of these genes in the human body might trigger an immune response. Additionally, where is the optimal balance between the induction dose of doxycycline and the reprogramming effect?

PressLife BiosciencesPlan, preliminary results may be available in2026End of the year or2027At the beginning of the year, the results will be released. If this trial is successful, it will demonstrate the feasibility of epigenetic reprogramming in humans, providing a foundation for subsequent research; if it fails or safety issues arise, it will also force the field to reconsider the technical approach and theoretical assumptions.

In any case,Life BiosciencesThis trial will provide important data for the entire anti-aging field and is worth attention.